8-11 November 2018 Amsterdam
![]() |
![]() |
![]() |
![]() |
P-005 | Follow-up and long-term comparison of the 8 and 12 cylinder scheme in prostate biopsy | Pau Sarrió-Sanz | ![]() |
![]() |
|||
P-006 | Improving Standard Trans-Rectal Prostate Biopsy Results Using High Resolution Micro-Ultrasound Real-Time Targeting for Suspicious Areas | Robert Sandler | ![]() |
![]() |
|||
P-007 | Initial Clinical Experience with 29 MHz Micro-Ultrasound for Real-Time Targeted Prostate Biopsies | Robert Sandler | ![]() |
![]() |
|||
P-008 | Where Do Micro-Ultrasound and MRI Find Prostate Cancer? A Target Localization Study | Robert Sandler | ![]() |
![]() |
|||
P-009 | Learning curve and distribution of PI-RADS score in a population based series of Norwegian men examined with a mpMRI detection protocol | Martin Landquist | ![]() |
![]() |
|||
P-010 | Assessment of ADC measurement using mpMRI in patients with low-risk prostate cancer (PCa) after radical prostatectomy (RP) | Dmitry Goncharuk | ![]() |
![]() |
|||
P-011 | Does high PIRADS V2 Score on a pre biopsies Multiparametric MRI scan suggest high-Gleason score prostate cancer? | Israr Khan | ![]() |
![]() |
|||
P-013 | Prostate cancer incidence related to favourable free/total PSA ratio. | Virginia del Rosario Rodriguez | ![]() |
![]() |
|||
P-020 | Validation and face to face comparison of three preoperative nomograms for prediction of lymph node invasion before radical prostatectomy | Angeles Sanchis-Bonet | ![]() |
![]() |
|||
P-021 | Should residents perform Laparoscopic Radical Prostatectomy? Datebase analysis | rodriguez lopez sabela | ![]() |
![]() |
|||
P-023 | Increasing Time from Diagnosis to Radical Prostatectomy (RP-interval) is Not Associated with Adverse Oncological Outcomes: Implications for cancer patient pathways (CPPs) | Kirsti Aas | ![]() |
![]() |
|||
P-040 | Correlation between the location of the index tumour and the location of positive lymph nodes in high-risk prostate cancer. A monocentric positive lymph node mapping study | Brecht Jacobs | ![]() |
![]() |
|||
P-041 | Effect of PectaSol-C modified citrus pectin (P-MCP) treatment (tx) on PSA Dynamics in non- metastatic Biochemically Relapsed Prostate Cancer (BRPC) patients (pts): Results of a prospective Phase II Study | Charles Hartmann | ![]() |
![]() |
|||
P-048 | Post-docetaxel survival in metastatic castration-resistant prostate cancer (mCRPC) is improving in the Netherlands | Malou Kuppen | ![]() |
![]() |
|||
P-049 | Efficacy of Abiraterone acetate plus Prednisone and Enzalutamide sequences in men with metastatic castration-resistant prostate cancer: Systematic review and meta-analysis | Paola Moreno | ![]() |
![]() |
|||
P-051 | Potential prognostic factors for metastatic castration resistant prostate cancer with Abiraterone Acetate | Cecília Maria de Melo Alvim Moreira | ![]() |
![]() |
|||
P-053 | Incidence of urological complications in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first line abiraterone and enzalutamide | JAVIER LORCA | ![]() |
![]() |
|||
P-055 | Enzalutamide in metastatic castration resistant prostate cancer, a single center experience | Rita Paiva | ![]() |
![]() |
|||
P-056 | A single-center experience with abiraterone acetate in metastatic castration resistant prostate cancer | Ana Afonso | ![]() |
![]() |
|||
P-058 | Survival impact of the management of medical and urological complications during treatment with 1st line abiraterone (A) or enzalutamide (E) in patients with metastatic castration-resistant prostate cancer (mCRPC) | Juan Jose Serrano Domingo | ![]() |
![]() |
|||
P-061 | Prognostic impact of end of radiotherapy PSA (EORT-PSA) on long-term outcomes in patients with N1 prostate cancer (PC) | Trude Wedde | ![]() |
![]() |
|||
P-063 | Prostate volume reduction in patients treated with Abiraterone and Enzalutamide: The forgotten outcome in Clinical trials | Sara Alvarez Rodríguez | ![]() |
![]() |
|||
P-064 | Exercise prescription dose for castration resistant prostate cancer patients: A phase I prescription dose escalation trial | Renée Bultijnck | ![]() |
![]() |
|||
P-067 | Risk of postoperative upstaging or upgrading among men with low-risk familial prostate cancer: PCBaSe Sweden | Fredrik Jansson | ![]() |
![]() |
|||
P-072 | Enzalutamide with or without prior anti-androgen treatment for castration resistant prostate cancer (CRPC): Results from the Dutch CAPRI registry | Malou Kuppen | ![]() |
![]() |
|||
P-082 | Multicenter registry of CRPC patients: Clinical characteristics and natural history of the disease | Victor Jose Valencia Guadalajara | ![]() |
![]() |
|||
P-087 | Isolation and characterization of urine exosomes for using as diagnostic biomarkers in Prostate Cancer | Angeles Sanchis-Bonet | ![]() |
![]() |
|||
P-095 | MRI for assessment of inferior vena cava wall invasion by renal cell carcinoma with vena cava thrombi | Tim van Oostenbrugge | ![]() |
![]() |
|||
P-100 | Dynamics of markers of acute kidney injury in renal cell carcinoma patients after laparoscopic partial nephrectomy under warm ischemia of the kidney | Sergey Dimitriadi | ![]() |
![]() |
|||
P-115 | Overall and progression free survival time in mRCC patients Clinicopathological risk group analysis | Joanna Huszno | ![]() |
![]() |
|||
P-116 | A lower psoas muscle volume correlates with a higher recurrence rate in male clear cell renal cell carcinoma patients | Go Noguchi | ![]() |
![]() |
|||
P-123 | Increased activation of mammalian target of rapamycin pathway in renal cell carcinoma arising in native kidneys of dialyzed patients | Ryuichi Mizuno | ![]() |
![]() |
|||
P-135 | Does neoadjuvant chemotherapy affect postoperative complication rates in elderly patients treated with radical cystectomy for bladder cancer? | Ryuichi Mizuno | ![]() |
![]() |
|||
P-136 | Could adjuvant chemotherapy have additional therapeutic benefit in muscle invasive bladder cancer patients treated with radical cystectomy and neoadjuvant chemotherapy? | Ryuichi Mizuno | ![]() |
![]() |
|||
P-149 | Monopolar transurethral resection of bladder tumors preformed by a urology resident: Is it safe for the patient? | Francisco José Damas Arroyo | ![]() |
![]() |
|||
P-152 | Predictors for development 30-day complications after radical cystectomy (RC) | Denis Ledyaev | ![]() |
![]() |
|||
P-153 | Pre-treatment lymphocytopenia predicts poor prognosis for patients with metastatic urothelial carcinoma treated with platinum-based first-line chemotherapy | Susumu Umemoto | ![]() |
![]() |
|||
P-163 | Expression of the microRNAs miR-100, miR-138 y miR-let-7c in non-muscle invasive bladder cancer: clinicopathological significance and prognostic value | ALVARO SANCHEZ GONZALEZ | ![]() |
![]() |
|||
P-165 | The role of frozen section examination (FSE) during inguinal exploration in 1052 patients with inconclusive testicular lesions | Christian Fankhauser | ![]() |
![]() |
|||
P-170 | Clinical analysis of extragonadal germ cell tumors in our hospital | Sohgo Tsutsumi | ![]() |
![]() |
8-11 November 2018 Amsterdam
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|